SCHEMBL2162492

SCHEMBL2162492

CC1OCc2sc(NC(=O)c3cc(F)ccc3Cl)c(C(=O)C3CCC3)c21

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ANO1 Q5XXA6 1/20 0.41
CNR2 P34972 7/20 0.37
CNR1 P21554 5/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TNF P01375 1/20 0.37
NOD1 Q9Y239 1/20 0.37
CFTR P13569 1/20 0.37
RXFP1 Q9HBX9 1/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2162482 0.79 CNR2 (0.52) ANO1CNR2CNR1KMT2A
SCHEMBL2162140 0.78 MAPT (0.46) MEN1KMT2ATP53MAPT
SCHEMBL2162358 0.76 CNR2 (0.50) CNR2CNR1MAPT
SCHEMBL2162421 0.74 CNR2 (0.50) CNR2CNR1MAPTTAS1R3TAS1R1
SCHEMBL2162128 0.73 CNR2 (0.44) RAB9ACNR2CNR1MEN1KMT2A
SCHEMBL2163174 0.71 CNR1 (0.37) NPC1RAB9ACNR2CNR1MEN1
SCHEMBL2162410 0.70 CNR1 (0.46) CNR2CNR1L3MBTL1
SCHEMBL2162084 0.69 ANO1 (0.54) ANO1CNR2CNR1MEN1KMT2A
SCHEMBL2162535 0.69 CNR2 (0.53) CNR2CNR1
SCHEMBL2163738 0.68 CNR2 (0.47) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US claimed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US claimed
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US disclosed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, OPRL1 NPC1 457/4885RAB9A 1073/4885ANO1 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.